Comprehensive AL Amyloidosis Market Summary, Epidemiology, Emerging Therapies, Competitive Landscape, Growth Trends, and Future Outlook Analysis

DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the AL amyloidosis, historical and forecasted epidemiology, and the AL Amyloidosis Market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the AL Amyloidosis Market Report @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from AL Amyloidosis Market Report
• In January 2026, Immix Biopharma announced that the FDA has granted Breakthrough Therapy Designation (BTD) to NXC-201 for the treatment of r/r AL Amyloidosis.
• AL amyloidosis primarily affects individuals aged 50-80 years, with males accounting for nearly two-thirds of the patient population.
• Delayed diagnosis remains a major challenge, with nearly 30% of patients dying within the first year following diagnosis.
• In the United States, AL amyloidosis is the most common form of amyloidosis, with approximately 4,500 new cases diagnosed annually.
• Among stage-specific cases, Stage II disease is the most prevalent (~45%), followed by Stage IIIa (~21%) and Stage IIIb (~19%).
• AL amyloidosis was identified as the most common amyloidosis subtype in Japan, accounting for ~48% of reported cases.
• The AL Amyloidosis Companies include Johnson & Johnson, AstraZeneca, Immix Biopharma, AbbVie, Amgen, and others.
• Promising AL Amyloidosis Therapies include anselamimab, etentamig, and NXC-201, among others.

Get a Free sample for the AL Amyloidosis Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is AL Amyloidosis?
Primary or light chain (AL) amyloidosis, the most common type of systemic amyloidosis, occurs when free light chains normally associated with immunoglobulins are produced in excess by clonal or frankly malignant plasma cells. Although not considered a cancer, it shares characteristics and treatments with multiple myeloma, and is most commonly diagnosed when patients have less than 10% bone marrow plasma cells, though it may also occur alongside multiple myeloma, non-Hodgkin's lymphoma, Waldenström's macroglobulinemia, chronic lymphocytic leukemia, Sjogren's syndrome, and Behçet's syndrome. Diagnosis begins with detection of monoclonal proteins via serum and urine immunofixation, serum free light chain testing, and 24-hour urine protein assessment, followed by tissue biopsy with Congo red staining to confirm amyloid deposition, with organ biomarkers and imaging used to evaluate organ involvement. Abdominal fat pad and bone marrow biopsies serve as common surrogate sites, with combined sensitivity of ~85%, and mass spectrometry-based proteomics is used to distinguish AL amyloidosis from other amyloid subtypes such as ATTR amyloidosis.

AL Amyloidosis Epidemiology Segmentation in the 7MM
• Total AL Amyloidosis Incident Cases
• AL Amyloidosis Incident Cases by Age
• AL Amyloidosis Incident Cases by Gender
• AL Amyloidosis Incident Cases by Stage
• Total AL Amyloidosis Treated Cases

Download the report to understand which factors are driving AL Amyloidosis epidemiology trends @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

AL Amyloidosis Approved Therapies
• Daratumumab and hyaluronidase-fihj (DARZALEX FASPRO): Johnson & Johnson
Daratumumab and hyaluronidase-fihj is the only CD38-directed antibody approved for subcutaneous administration in multiple myeloma and now AL amyloidosis, co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) using Halozyme's ENHANZE drug delivery technology. It received accelerated FDA approval in January 2021 for newly diagnosed AL amyloidosis, followed by traditional FDA approval on November 19, 2025.

AL Amyloidosis Pipeline Analysis
• Anselamimab: AstraZeneca
Anselamimab is an investigational, potentially first-in-class anti-fibril monoclonal antibody designed to improve organ function by reducing or eliminating amyloid deposits, binding misfolded amyloid fibrils to promote their destruction and clearance while sparing native free light chains. It holds Fast Track and Orphan Drug Designations from the US FDA, European Commission, and Japan's Ministry of Health, Labour and Welfare. However, in July 2025, anselamimab failed to meet the primary endpoint in two Phase III CARES trials, showing no statistically significant reduction in overall mortality, though subgroup analyses showed clinically meaningful benefit in selected populations, prompting AstraZeneca to pursue continued regulatory discussions, with a first regulatory decision anticipated in H2 2026.

• Etentamig: AbbVie/Amgen
Etentamig is a BCMA x CD3-targeted investigational therapy designed to reduce pathogenic plasma cell activity and lower amyloidogenic light chains, currently in Phase II trials for AL amyloidosis. Additional preliminary dose-escalation data with etentamig monotherapy in r/r AL amyloidosis were presented at the 2025 ASH annual meeting.

• NXC-201: Immix Biopharma
NXC-201 is a BCMA-targeted CAR-T therapy in Phase I/II development for r/r AL amyloidosis. In January 2026, the FDA granted Breakthrough Therapy Designation to NXC-201, following interim Phase II results from the NEXICART-2 trial presented at the December 2025 ASH annual meeting.

AL Amyloidosis Companies
Johnson & Johnson, AstraZeneca, Immix Biopharma, AbbVie, Amgen, and others

Discover more about therapies set to grab major AL Amyloidosis market share @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

AL Amyloidosis Market Outlook
The AL amyloidosis treatment market is undergoing a significant transformation, evolving beyond traditional plasma cell-directed regimens toward organ-targeted and disease-modifying therapeutic strategies. Historically, treatment relied on adapted multiple myeloma regimens, including proteasome inhibitors such as bortezomib, alkylating agents like cyclophosphamide, corticosteroids, and ASCT in eligible patients. The approval of daratumumab and hyaluronidase-fihj in combination with CyBorD established the first FDA-approved standard of care regimen specifically for newly diagnosed AL amyloidosis, significantly improving hematologic response rates. Despite this, substantial unmet need remains due to persistent organ dysfunction, high early mortality in advanced cardiac disease, and limited options for relapsed or refractory patients. Anselamimab's Phase III setback, alongside continued progress from etentamig and NXC-201, underscores a broader shift toward organ-targeted antibodies, biologics, and CAR-T cell therapies expected to reshape the AL amyloidosis landscape in the 7MM.

Scope of the AL Amyloidosis Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Forecast Period: 2026-2036
• Base Year: 2026
• Coverage: 7MM (US; EU4 - Germany, France, Italy, Spain; UK; Japan)
• AL Amyloidosis Companies: Johnson & Johnson, AstraZeneca, Immix Biopharma, AbbVie, Amgen, and others
• AL Amyloidosis Therapies: Daratumumab-hyaluronidase (DARZALEX FASPRO), NXC-201, Anselamimab, Etentamig, among others
• AL Amyloidosis Market Segmented by: Region/Geographies, Drugs/Therapies
• Analysis: Addressable Patient Population, Market Drivers and Barriers, Cost Assumptions and Pricing Analogues, KOL Views, SWOT Analysis, Reimbursement, Conjoint Analysis, Unmet Need

To know more about AL Amyloidosis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology of AL Amyloidosis
6. AL Amyloidosis Market Overview at a Glance
7. Disease Background and Overview of AL Amyloidosis
8. Epidemiology and Patient Population of AL Amyloidosis
9. Patient Journey of AL Amyloidosis
10. Marketed Therapies of AL Amyloidosis
11. Emerging Therapies of AL Amyloidosis
12. AL Amyloidosis: 7MM Analysis
13. Unmet Needs of AL Amyloidosis
14. SWOT Analysis of AL Amyloidosis
15. KOL Views of AL Amyloidosis
16. Market Access and Reimbursement of AL Amyloidosis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.